Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.16 +0.5%	$3.30	$2.71 ▼ $4.73	$604.27M	1.2	946,231 shs	186,417 shs
ARVN Arvinas	$7.61 +1.2%	$7.30	$5.90 ▼ $30.31	$558.75M	2.17	1.50 million shs	820,184 shs
FSTX F-star Therapeutics	$7.12	$6.19	$2.07 ▼ $7.12	$156.50M	0.85	709,213 shs	N/A
KALV KalVista Pharmaceuticals	$15.64 +0.5%	$12.89	$7.30 ▼ $16.32	$779.53M	-0.04	590,458 shs	458,446 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+0.32%	-3.09%	-8.45%	-1.57%	-14.91%
ARVN Arvinas	+2.31%	-4.45%	+1.08%	-15.88%	-73.63%
FSTX F-star Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
KALV KalVista Pharmaceuticals	+1.10%	+2.23%	+28.07%	+26.50%	+6.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	1.5806 of 5 stars	3.5	0.0	0.0	0.0	0.6	2.5	0.6
ARVN Arvinas	3.9019 of 5 stars	4.3	4.0	0.0	0.0	1.9	2.5	1.3
FSTX F-star Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	4.1849 of 5 stars	3.6	1.0	0.0	4.4	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	74.33% Upside
ARVN Arvinas	2.55	Moderate Buy	$20.29	166.58% Upside
FSTX F-star Therapeutics	0.00	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	68.08% Upside

Current Analyst Ratings Breakdown

Latest FSTX, ARVN, KALV, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
6/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
6/2/2025	ARVN Arvinas	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$10.00 ➝ $9.00
6/1/2025	ARVN Arvinas	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/15/2025	ARVN Arvinas	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $21.00
5/9/2025	ARVN Arvinas	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$12.00 ➝ $11.00
5/5/2025	ARVN Arvinas	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.50
5/5/2025	ARVN Arvinas	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $10.00
5/5/2025	ARVN Arvinas	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$21.00 ➝ $11.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.40M	94.37	N/A	N/A	$0.51 per share	6.19
ARVN Arvinas	$426.90M	1.30	N/A	N/A	$8.17 per share	0.93
FSTX F-star Therapeutics	$21.17M	7.39	N/A	N/A	$4.70 per share	1.51
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.41	N/A	N/A	N/A	-1,196.64%	-75.51%	-55.81%	8/7/2025 (Estimated)
ARVN Arvinas	-$198.90M	-$0.66	N/A	N/A	N/A	-10.92%	-7.74%	-4.11%	7/29/2025 (Estimated)
FSTX F-star Therapeutics	-$31.28M	-$1.82	N/A	N/A	N/A	N/A	-57.08%	-42.40%	N/A
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)

Latest FSTX, ARVN, KALV, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q2 2025	ARVN Arvinas	-$0.87	N/A	N/A	N/A	$34.42 million	N/A
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/1/2025	Q1 2025	ARVN Arvinas	-$0.93	$1.14	+$2.07	$1.14	$41.87 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
FSTX F-star Therapeutics	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	0.04	6.01	6.01
ARVN Arvinas	N/A	4.58	4.58
FSTX F-star Therapeutics	0.15	3.38	3.38
KALV KalVista Pharmaceuticals	N/A	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ARVN Arvinas	95.19%
FSTX F-star Therapeutics	31.50%
KALV KalVista Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
ARVN Arvinas	4.73%
FSTX F-star Therapeutics	3.20%
KALV KalVista Pharmaceuticals	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	152.65 million	Optionable
ARVN Arvinas	420	72.99 million	69.54 million	Optionable
FSTX F-star Therapeutics	84	21.98 million	21.28 million	Not Optionable
KALV KalVista Pharmaceuticals	100	49.95 million	44.71 million	Optionable

FSTX, ARVN, KALV, and ABUS Headlines

Recent News About These Companies

KalVista Pharmaceuticals receives UK MKRA marketing authorization for sebetralstat to treat hereditary angioedema attacks

July 18, 2025 | pharmabiz.comP

MHRA approves KalVista’ Ekterly to treat hereditary angioedema attacks

July 17, 2025 | pmlive.comP

Cantor Fitzgerald Issues Positive Forecast for KALV Earnings

July 16, 2025 | marketbeat.com

KalVista Gets U.K. Authorization for Hereditary Angioedema Treatment

July 15, 2025 | marketwatch.com

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

July 15, 2025 | finance.yahoo.com

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLYÂ® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

July 15, 2025 | businesswire.com

MHRA approves Ekterly to treat HAE

July 15, 2025 | thepharmaletter.comT

The week in pharma: action, reaction and insight – week to July 11

July 13, 2025 | thepharmaletter.comT

Emerald Advisers LLC Has $10.37 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

July 13, 2025 | marketbeat.com

KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down on Disappointing Earnings

July 13, 2025 | americanbankingnews.com

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year ...

July 12, 2025 | seekingalpha.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Emerald Mutual Fund Advisers Trust

July 12, 2025 | marketbeat.com

Leerink Partnrs Has Positive Outlook of KALV Q3 Earnings

July 12, 2025 | americanbankingnews.com

HC Wainwright Has Bullish Forecast for KALV Q4 Earnings

July 12, 2025 | americanbankingnews.com

KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Down After Earnings Miss

July 11, 2025 | marketbeat.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 32,979 Shares

July 11, 2025 | insidertrades.com

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Expected to Rise, HC Wainwright Analyst Says

July 11, 2025 | americanbankingnews.com

KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 5.5% Following Analyst Upgrade

July 11, 2025 | americanbankingnews.com

KalVista Pharmaceuticals: EKTERLY Launch and Financial Update

July 10, 2025 | tipranks.com

Benjamin L. Palleiko Sells 32,979 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

July 10, 2025 | marketbeat.com

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

July 10, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

FSTX, ARVN, KALV, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.16 +0.02 (+0.48%)

As of 03:04 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arvinas NASDAQ:ARVN

$7.61 +0.09 (+1.21%)

As of 03:04 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

F-star Therapeutics NASDAQ:FSTX

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

KalVista Pharmaceuticals NASDAQ:KALV

$15.64 +0.08 (+0.51%)

As of 03:04 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time